These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17681022)

  • 21. Effects of a polypharmacy edit and reduced quantity limits on the utilization of triptans and overall costs in an integrated health system.
    Dunn JD; Cannon HE
    Manag Care Interface; 2006 May; 19(5):46-51. PubMed ID: 16786970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of triptans in Sweden; analyses of over the counter and prescription sales.
    von Euler M; Keshani S; Baatz K; Wettermark B
    Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1288-93. PubMed ID: 25044442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients].
    Pascual J; Navarro A; Caminero AB; Jurado C; Díaz-Insa S; Huerta M
    Neurologia; 2006 May; 21(4):188-91. PubMed ID: 16832773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Almotriptan in triptan-naïve patients: new evidence of benefits.
    Pascual J
    Cephalalgia; 2008 Sep; 28 Suppl 2():14-20. PubMed ID: 18715328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptan use in Australia 1997-2015: A pharmacoepidemiological study.
    Eyre BLKD; Eadie MJ; van Driel ML; Ross-Lee L; Hollingworth SA
    Acta Neurol Scand; 2017 Aug; 136(2):155-159. PubMed ID: 28093722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
    Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
    Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of use and health expenses associated with triptans among adults with migraines.
    Wu J; Noxon V; Lu ZK
    Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment.
    Tfelt-Hansen P
    Headache; 2008 Apr; 48(4):601-5. PubMed ID: 18377382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty-five years of triptans - a nationwide population study.
    Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
    Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Triptans--pivotal event in migraine treatment].
    Lusić I; Bilić I
    Acta Med Croatica; 2008 May; 62(2):173-8. PubMed ID: 18710081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy.
    Biagi C; Poluzzi E; Roberto G; Puccini A; Vaccheri A; D'Alessandro R; Motola D; Montanaro N
    Eur J Clin Pharmacol; 2011 Dec; 67(12):1283-9. PubMed ID: 21674159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment adherence among new triptan users: a 2-year cohort study in Taiwan.
    Chen TB; Chen YT; Fuh JL; Tang CH; Wang SJ
    J Headache Pain; 2014 Aug; 15(1):48. PubMed ID: 25117594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.
    Cady RK; Banks J; Jones BA; Campbell J
    Curr Med Res Opin; 2009 Nov; 25(11):2711-21. PubMed ID: 19778164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.
    Sacco S; Di Ciaccio S; Di Virgilio R; Pegoraro V; Ornello R
    Neurol Sci; 2024 Sep; 45(9):4427-4435. PubMed ID: 38538924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden.
    Bigal M; Rapoport A; Aurora S; Sheftell F; Tepper S; Dahlof C
    Headache; 2007 Apr; 47(4):475-9. PubMed ID: 17445096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
    Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
    Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic issues associated with switching between triptans in clinical practice.
    Dowson AJ; Fuat A; Gruffydd-Jones K
    Curr Med Res Opin; 2005 Mar; 21(3):375-9. PubMed ID: 15811206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of sinus headache as migraine: the diagnostic utility of triptans.
    Kari E; DelGaudio JM
    Laryngoscope; 2008 Dec; 118(12):2235-9. PubMed ID: 18948830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.